Prescient Therapeutics improves manufacturing route for PTX-100
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX) has today advised it has identified an improved manufacturing route for PTX-100 for use in its upcoming pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial.
The new route has several advantages over the previous method, which are:
- Yielding twice as much drug product;
- Enabling a more meaningful number of patients to be treated in the upcoming study;
- Similar cost to the old method; and
- Regulatory compliance for all phases of study (whereas the old method was suitable only for phase 1).
Given that the manufacture of PTX-100 is a complex process, the company — led by Dr Mike Preigh, VP Chemistry, Manufacturing & Controls — has worked hard to achieve this improved manufacturing route, while at the same time keeping down the extensive costs that would otherwise be incurred.
PTX is planning a program for PTX-100 which will advance the asset towards a crucial PK and PD study for several malignancies, with the company expecting a PK/PD trial to initiate in early 2019. This trial will involve a more meaningful number of patients and will therefore be a more informative and productive study, and conducted to a higher regulatory standard.
The company is also in the planning stages for the manufacture of a new batch of active pharmaceutical ingredient (API) as a precursor to manufacturing additional PTX-200 drug product required for ongoing clinical trials, with the process proceeding on schedule.
Prescient CEO and Managing Director, Steven Yatomi-Clarke commented on today’s update: “Chemistry, Manufacturing and Controls (CMC) are a crucial part of drug development and clinical trials, although often unseen and under-appreciated.
“Prescient has invested in robust CMC programs for both assets which will hold it in good stead going forward,” he said.
Of course, it should be noted that PTX is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
Last week, the small cap updated the market on its trial of PTX-200 with cytarabine in relapsed or refractory acute myeloid leukaemia (AML).
Encouraging efficacy signals were seen as PTX looks to expand the current study to optimise Akt inhibition in the combination therapy.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.